SCM
RAPT

Silverarc Capital Management’s RAPT Therapeutics RAPT Stock Holding History

Silverarc Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,475
Closed -$366K – 86
2021
Q3 		$366K Sell
1,475
-4,424
-75% -$1.17M 0.21% 75
2021
Q2 		$1.5K Buy
+5,899
New +$1.1M 0.67% 55

Other funds holding RAPT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Silverarc Capital Management's RAPT Position: Q4 2021 in Review

Silverarc Capital Management sold out of RAPT Therapeutics (RAPT) in Q4 2021, closing a stake of 1,475 shares — an estimated $366K sold.

Silverarc Capital Management first reported a position in RAPT in Q2 2021 and held it in 2 quarters. The position peaked at $366K in Q3 2021. 99 funds tracked by Wall St. Rank hold RAPT as of Q4 2021.

  • Silverarc Capital Management reported no remaining RAPT Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 1,475 RAPT Therapeutics shares in Q4 2021, an estimated $366K.
  • Silverarc Capital Management first reported a position in RAPT Therapeutics in Q2 2021 and held it in 2 quarters.
  • Silverarc Capital Management's RAPT Therapeutics position peaked at $366K in Q3 2021.
  • 99 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2021.

Based on Silverarc Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.